Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pleckstrin homology-like domain family A member 3 (PHLDA3)
- Target
- PHLDA3
- Molecular classification
- Other (PH domain-only protein; not in a classical receptor/enzyme/ion-channel family)
01
Overview
Pleckstrin homology-like domain family A member 3 (PHLDA3) is a p53-regulated, PH domain-only protein that functions primarily as a repressor of Akt (protein kinase B) signaling. PHLDA3 competes with the PH domain of Akt for binding to membrane lipids, preventing Akt activation and thereby promoting p53-dependent apoptosis and inhibiting cell survival. Loss or reduced expression of PHLDA3 has been associated with increased Akt activity and reduced apoptosis, contributing to tumorigenesis, including in lung and prostate cancer. PHLDA3 is considered a tumor suppressor and may serve as a biomarker for loss of apoptotic regulation in certain cancers
- Other names
- TIH1TDAG51/Ipl homolog 1Pleckstrin homology-like domain, family A, member 2 (note: likely a misattribution; canonical is "member 3")TSSC3 protein (Phlda3)
02
Mechanism of action
N/A for drugs (the molecule acts by repressing Akt signaling via competitive PH domain binding to membrane lipids, downstream of p53; not itself a direct drug target at present)
03
Biological functions
Negative regulation of PI3K/Akt signaling pathwayApoptosis (p53-mediated)Tumor suppression
04
Disease associations
Cancer (tumor suppressor function, genomic loss observed in lung cancer, involvement in prostate cancer)Multiple endocrine neoplasia type I (gene-disease association)
05
Safety considerations
No direct therapeutic safety concerns reported (since no approved drugs target PHLDA3 directly; possible risks from modulating apoptosis/tumor suppression pathways)
06
Interacting drugs
None directly listed in current authoritative sources; no approved drugs known to specifically interact with or target PHLDA3
07
Biomarkers
Genomic loss in lung cancer (potential biomarker for tumor suppressor loss)PHLDA3 expression levels (potential marker for PI3K/Akt pathway activity and p53-dependent apoptosis)
Beyond the preview
Go deeper on Pleckstrin homology-like domain family A member 3 (PHLDA3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pleckstrin homology-like domain family A member 3 (PHLDA3).